Reuters
30 Jun 2026, 05:24 UTC · 2h ago
Metis TechBio in deal for experimental autoimmune drug worth up to $1.6 billion
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Reuters
30 Jun 2026, 05:24 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
Metis TechBio entered a deal with Boulevard Bio that could be worth up to $1.6 billion for the development of its autoimmune drug MTS-128. — The potential for a billion-dollar payout significantly increases the valuation and cash-flow expectations for Metis TechBio.
+0.80Boulevard Bio has been granted exclusive global rights to develop, manufacture, and commercialize MTS-128. — Exclusive global rights transfer the commercial risk and execution to a partner, validating the asset's potential while limiting Metis's direct control.
+0.40Which stocks this story touches
The company secured a licensing deal for its drug candidate potentially worth up to $1.6 billion.
Continue reading
6 related stories
Top 1 mover · tap to explore
[mutual] Metis TechBio granted Boulevard Bio exclusive global rights to develop and commercialise its drug MTS-128.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
1h ago
